Table 3.
Summary table about the differences between Candida spp. and Aspergillus spp. groups.
| Candida spp. (n = 23) | Aspergillus spp. (n = 7) | p-value | |
|---|---|---|---|
| Age (±SD) | 62 (7.1) | 60.5 (14) | 0.560 |
| Sex (M:F) | 62.5:37.5 | 71.4:28.6 | 0.664 |
| Frail Index (±SD) | 1.56 (0.53) | 0.5 (0.7) | 0.254 |
| Charlson index (±SD) | 2.06 (4) | 2 (2.8) | 0.079 |
| MuLBSTA (±SD) | 12.13 (1.6) | 10 (4.2) | 0.693 |
| CURB-65 (±SD) | 1.60 (0.55) | 0.5 (0.7) | 0.074 |
| Lymphocytes (±SD) | 750 (3,162) | 1,500 (6,393) | 0,337 |
| C-protein reactive (±SD) | 17.5 (6.7) | 29 (15.6) | 0.481 |
| Dimer-D (±SD) | 1,669 (2,807) | 505 (558) | 0.595 |
| LDH (±SD) | 500 (210) | 473 (70) | 0.869 |
| Ferritin (±SD) | 1,549 (1,295) | 1,664 (1,725) | 0.918 |
| PaO2/FiO2 (±SD) | 123 (43.5) | 136.4 (118) | 0.598 |
| SpO2/FiO2 (±SD) | 79.18 (21) | 123.7 (64) | 0.04 |
| HACOR index (±SD) | 5.71 (1.9) | 4 (5.6) | 0.742 |
| ROX index (±SD) | 3.4 (1) | 4 (2.7) | 0.804 |
| ARDS classification: | |||
| n (%) | |||
| Moderate | 7 (30) | 1 (14.3) | 0.150 |
| Severe | 11 (70) | 6 (85.7) | |
| Radiological involvement: | |||
| n (%) | |||
| Mild | 0 | 0 | |
| Moderate | 2 (7) | 1 (14.3) | 0.218 |
| Severe | 21 (93) | 6 (85.7) | |
| Immunosuppressants drugs: | |||
| n (%) | |||
| Tocilizumab | 16 (51.6) | 5 (71.4) | 0.846 |
| Cyclosporine | 5 (16.1) | 1 (14.2) | 0.430 |
| Corticosteroids | 27 (87.1) | 4 (57.1) | 0.05 |
| OTI n (%) | 23 (100) | 7 (100) | 1 |
| Days admission (±SD) | 31.6 (7.2) | 32.3 (14) | 0.212 |
| ICU days admission (±SD) | 21.7 (11.5) | 27.3 (12.4) | 0.818 |
| Death n (%) | 20 (87) | 6 (86) | 0.950 |
Differences between the clinical, radiological, gas exchange and severity findings of COVID-19 were analyzed. SD: Standard deviation LDH: lactate dehydrogenase ARDS: Adult respiratory distress syndrome ICU: Intensive Care Unit OTI: orotracheal intubation.